Summary:
We are pleased to share information about a clinical study of an investigational vaccine for seniors that may help protect you from the severe effects of Respiratory Syncytial Virus (RSV) infection.
RSV is a highly infectious virus that can cause respiratory illness in all age groups, but it can be
especially severe in older adults. RSV often begins with a fever and cold symptoms that may lead to more severe infections and conditions such as bronchiolitis, chronic obstructive pulmonary disease, pneumonia, asthma, and respiratory failure.
In the VANIR Study, local doctors are assessing if the study vaccine, called MVA-BN-RSV, can help protect seniors from this common health threat.
You may be able to join this study if you:
- Are 60 years of age or older
- Are in good general health, or have only mild to moderate conditions that are well-managed
- Are comfortable using an app on a mobile phone or other device to report symptoms and communicate with the study team once a month
If you pre-qualify, the study team will discuss additional criteria with you and answer any questions you may have about the VANIR Study.